| Date |
Report No. |
Title |
| Date Nov. 1, 2002 |
Report No. GAO-03-189 |
Title
United States General Accounting Office GAO
November 2002 Report to the Chairman, Subcommittee on Criminal Justice, Drug Policy and Human Resources, Committee on Government Reform, U.S. House of Representatives MARIJUANA Early Experiences with Four States’ Laws That Allow Use for Medical Purposes GAO-03-189 Contents Letter
Results in Brief Background Implementation in Oregon, Alaska, Hawaii, and... |
| Date Oct. 28, 2002 |
Report No. GAO-03-177 |
Title
United States General Accounting Office GAO
October 2002 Report to Congressional Requesters PRESCRIPTION DRUGS FDA Oversight of Direct-to-Consumer Advertising Has Limitations GAO-03-177 Contents Letter
Results in Brief Background Pharmaceutical Companies Spend More on Research and Development than on DTC Advertising DTC Advertising Appears to Increase Prescription Drug Spending and Utilization FDA... |
| Date Sept. 27, 2002 |
Report No. GAO-02-1017 |
Title
United States General Accounting Office GAO
September 2002 Report to Chairman, Subcommittee on Defense, Committee on Appropriations, U.S. Senate VA AND DEFENSE HEALTH CARE Increased Risk of Medication Errors for Shared Patients GAO-02-1017 Contents Letter
Results in Brief Background Shared Patients Obtain Inpatient Drugs from the Treating Agency but Generally Return to Home Agency for Outpatient D... |
| Date Sept. 17, 2002 |
Report No. GAO-02-958 |
Title
United States General Accounting Office GAO
September 2002 Report to the Chairman, Committee on Health, Education, Labor, and Pensions, U.S. Senate FOOD AND DRUG ADMINISTRATION Effect of User Fees on Drug Approval Times, Withdrawals, and Other Agency Activities GAO-02-958 Contents Letter
Results in Brief Background PDUFA Has Increased Funding and Reduced Drug Approval Time, but Biologic Approval T... |
| Date July 31, 2002 |
Report No. GAO-02-985T |
Title
United States General Accounting Office GAO Testimony
Before the Subcommittee on Oversight of Government Management, Restructuring, and the District of Columbia, Committee on Governmental Affairs, U.S. Senate For Release on Delivery Expected at 10:00 a.m. Wednesday, July 31, 2002 DIETARY SUPPLEMENTS FOR WEIGHT LOSS Limited Federal Oversight Has Focused More on Marketing than on Safety
Statement of... |
| Date July 22, 2002 |
Report No. GAO-02-969T |
Title
United States General Accounting Office GAO Testimony
Before the Subcommittee on National Security, Veterans Affairs, and International Relations, Committee on Government Reform, House of Representatives For Release on Delivery Expected at 9:30 a.m. in Boston, Massachusetts Monday, July 22, 2002 VA AND DOD HEALTH CARE Factors Contributing to Reduced Pharmacy Costs and Continuing Challenges
Stateme... |
| Date June 26, 2002 |
Report No. GAO-02-872T |
Title
United States General Accounting Office GAO Testimony
Before the Subcommittee on Health, Committee on Veterans’ Affairs, House of Representatives For Release on Delivery Expected at 9:30 a.m. Wednesday, June 26, 2002 VA AND DEFENSE HEALTH CARE Potential Exists for Savings through Joint Purchasing of Medical and Surgical Supplies
Statement of Cynthia A. Bascetta Director, Health Care—Veterans... |
| Date June 12, 2002 |
Report No. GAO-02-833T |
Title
United States General Accounting Office GAO Testimony
Before the Subcommittee on Labor, Health and Human Services, Education and Related Agencies, Committee on Appropriations, U.S. Senate For Release on Delivery Expected at 9:30 a.m. Wednesday, June 12, 2002 MEDICARE Challenges Remain in Setting Payments for Medical Equipment and Supplies and Covered Drugs
Statement of Leslie G. Aronovitz Director... |
| Date April 29, 2002 |
Report No. GAO-02-579 |
Title
United States General Accounting Office GAO
April 2002 Report to the Chairman, Committee on Veterans’ Affairs, House of Representatives VA HEALTH CARE Implementation of Prescribing Guideline for Atypical Antipsychotic Drugs Generally Sound GAO-02-579 a Contents Letter
Results in Brief Background VA Prescribing Guideline for Atypical Antipsychotic Drugs Is Sound Guideline Generally Implemented as... |
| Date April 17, 2002 |
Report No. GAO-02-643T |
Title
United States General Accounting Office GAO Testimony
Before the Committee on Ways and Means, House of Representatives For Release on Delivery Expected at 10:30 a.m. Wednesday, April 17, 2002 MEDICARE Financial Outlook Poses Challenges for Sustaining Program and Adding Drug Coverage
Statement of David M. Walker Comptroller General of the United States GAO-02-643T Mr. Chairman and Members of the Co... |
| Date March 29, 2002 |
Report No. GAO-02-416 |
Title
United States General Accounting Office GAO
March 2002 Report to the Co-Chairman, Caucus on International Narcotics Control, U.S. Senate DRUG CONTROL DEA Could Improve Its Heroin Signature and Domestic Monitor Programs' Geographic Source Data GAO-02-416 Contents Letter
Results in Brief Background Scope and Methodology Purpose of the HSP and DMP Is To Produce Data That Detect Trends in Heroin Sourc... |
| Date March 14, 2002 |
Report No. GAO-02-533T |
Title
United States General Accounting Office GAO Testimony
Before the Subcommittee on Health, Committee on Ways and Means, House of Representatives For Release on Delivery Expected at 2:15 p.m. Thursday, March 14, 2002 MEDIGAP Current Policies Contain Coverage Gaps, Undermine Cost Control Incentives
Statement of William J. Scanlon Director, Health Care Issues GAO-02-533T Madam Chairwoman and Members of... |
| Date March 14, 2002 |
Report No. GAO-02-531T |
Title
United States General Accounting Office GAO Testimony
Before the Subcommittee on Health, Committee on Finance, U.S. Senate For Release on Delivery Expected at 10:00 a.m. Thursday, March 14, 2002 MEDICARE OUTPATIENT DRUGS Program Payments Should Better Reflect Market Prices
Statement of Laura A. Dummit Director, Health Care—Medicare Payment Issues GAO-02-531T Mr. Chairman and Members of the Subco... |
| Date Feb. 13, 2002 |
Report No. GAO-02-276R |
Title
United States General Accounting Office Washington, DC 20548 February 13, 2002 The Honorable Jeff Sessions United States Senate Subject: The Drug Enforcement Administration’s Reporting of Arrests Dear Senator Sessions: The mission of the Drug Enforcement Administration (DEA) is to enforce U.S. laws and regulations regarding controlled substances and to help bring to justice those involved in gro... |
| Date Feb. 8, 2002 |
Report No. GAO-02-291 |
Title
United States General Accounting Office GAO
February 2002 Report to Congressional Requesters DRUG CONTROL Efforts to Develop Alternatives to Cultivating Illicit Crops in Colombia Have Made Little Progress and Face Serious Obstacles GAO-02-291 a Contents Letter Results in Brief Background Progress Requires Strong Host Government Commitment and Sustained U.S. Assistance USAID Alternative Development... |
| Date Jan. 25, 2002 |
Report No. GAO-02-13 |
Title
United States General Accounting Office GAO
January 2002 Report to the Honorable Jeff Sessions U.S. Senate DRUG CONTROL Difficulties in Measuring Costs and Results of Transit Zone Interdiction Efforts GAO-02-13 Contents Letter Results in Brief Background Interdiction Roles of DOD, the Coast Guard, and Customs Overlap Agencies Do Not Track Funds Obligated and Assets Used for Transit Zone Interdicti... |
| Date Dec. 7, 2001 |
Report No. GAO-02-42 |
Title
United States General Accounting Office GAO
December 2001 Report to the Ranking Minority Member, Committee on Governmental Affairs, U.S. Senate DEPARTMENT OF STATE Status of Achieving Key Outcomes and Addressing Major Management Challenges GAO-02-42 Contents Letter
Results in Brief Background Assessment of State’s Progress and Strategies in Accomplishing Selected Key Outcomes Comparison of State... |
| Date Dec. 5, 2001 |
Report No. GAO-02-280R |
Title
United States General Accounting Office Washington, DC 20548 December 5, 2001 Congressional Requesters Subject: Prescription Drugs: Prices Available Through Discount Cards and From Other Sources This letter responds to your request for information on how the prices for prescription drugs purchased using drug discount cards compare with the prices available at local pharmacies or over the Internet.... |
| Date Sept. 21, 2001 |
Report No. GAO-01-1118 |
Title
United States General Accounting Office GAO
September 2001 Report to Congressional Committees MEDICARE Payments for Covered Outpatient Drugs Exceed Providers’ Cost GAO-01-1118 Contents Letter
Results in Brief Background Physicians Can Obtain Drugs Covered Under Part B for Significantly Less Than Medicare Payments Medicare Drug Payments Also Substantially Higher Than Costs for Pharmacy Supplier-B... |
| Date Sept. 21, 2001 |
Report No. GAO-01-1142T |
Title
United States General Accounting Office GAO Testimony
Before the Subcommittee on Health and the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives For Release on Delivery Expected at 9:30 a.m. Friday, September 21, 2001 MEDICARE PART B DRUGS Program Payments Should Reflect Market Prices
Statement of William J. Scanlon Director, Health Care Issu... |
| Date Sept. 14, 2001 |
Report No. GAO-01-1011 |
Title
United States General Accounting Office GAO
September 2001 Report to Congressional Requesters ATTENTION DISORDER DRUGS Few Incidents of Diversion or Abuse Identified by Schools GAO-01-1011 Contents Letter
Results in Brief Background Few Incidents of Diversion or Abuse of Attention Disorder Drugs Identified by Schools Most Schools Dispense Attention Disorder Medications and Follow Drug Security Pro... |
| Date Sept. 10, 2001 |
Report No. GAO-01-1139T |
Title
United States General Accounting Office GAO Testimony
Before the Special Committee on Aging, U.S. Senate For Release on Delivery Expected at 10:00 a.m. Monday, September 10, 2001 HEALTH PRODUCTS FOR SENIORS Potential Harm From “Anti-Aging” Products
Statement of Janet Heinrich Director, Health Care—Public Health Issues GAO-01-1139T Mr. Chairman and Members of the Committee: I am pleased to ha... |
| Date Sept. 7, 2001 |
Report No. GAO-01-1129 |
Title
United States General Accounting Office GAO
September 2001 Report to Chairman, Special Committee on Aging, U.S. Senate HEALTH PRODUCTS FOR SENIORS “Anti-Aging” Products Pose Potential for Physical and Economic Harm GAO-01-1129 Contents Letter
Results in Brief Background Some Dietary Supplements Have Been Associated With Potentially Serious Health Consequences for Senior Citizens Senior Citizen... |
| Date Aug. 1, 2001 |
Report No. GAO-01-1017T |
Title
United States General Accounting Office GAO Testimony
Before the Subcommittee on Criminal Justice, Drug Policy and Human Resources Committee on Government Reform House of Representatives For Release on Delivery Expected at 10 a.m. EDT Wednesday August, 1, 2001 ANTI-DRUG MEDIA CAMPAIGN Aspects of Advertising Contract Mismanaged by the Government; Contractor Improperly Charged Some Costs
Statement o... |
| Date July 31, 2001 |
Report No. GAO-01-941 |
Title
United States General Accounting Office GAO
July 2001 Report to Congressional Committees MEDIGAP INSURANCE Plans Are Widely Available but Have Limited Benefits and May Have High Costs GAO-01-941 Contents Letter
Results in Brief Background Medigap Enrollment Exceeds 10 Million, Mostly Concentrated in Two Plans Medigap Plans Are Widely Available in Most States, But Access May Be Limited for Certain ... |
| Date July 25, 2001 |
Report No. GAO-01-1010T |
Title
United States General Accounting Office GAO Testimony
Before the Committee on the Budget, House of Representatives For Release on Delivery Expected at 10:00 a.m. Wednesday, July 25, 2001 MEDICARE New Spending Estimates Underscore Need for Reform
Statement of David M. Walker Comptroller General of the United States GAO-01-1010T Mr. Chairman and Members of the Committee: I am pleased to be here toda... |
| Date July 24, 2001 |
Report No. GAO-01-998T |
Title
United States General Accounting Office GAO Testimony
Before the Committee on Veterans' Affairs, U.S. Senate For Release on Delivery Expected at 2:30 p.m. Tuesday, July 24, 2001 VA HEALTH CARE Continuing Oversight Needed to Achieve Formulary Goals
Statement of Cynthia A. Bascetta Director, Health Care—Veterans’ Health Care and Benefits Issues GAO-01-998T Mr. Chairman and Members of the Committ... |
| Date July 6, 2001 |
Report No. GAO-01-754 |
Title
United States General Accounting Office GAO
July 2001 Report to Congressional Requesters WOMEN’S HEALTH Women Sufficiently Represented in New Drug Testing, but FDA Oversight Needs Improvement GAO-01-754 Contents Letter
Results in Brief Background FDA’s Regulation Not As Specific As Earlier Guidance NDA and IND Submissions Often Fail to Present Required Information NDAs Include Appropriate Numb... |
| Date May 25, 2001 |
Report No. GAO-01-588 |
Title
United States General Accounting Office GAO
May 2001 Report to Congressional Requesters DOD AND VA PHARMACY Progress and Remaining Challenges in Jointly Buying and Mailing Out Drugs GAO-01-588 Contents Letter Appendix I Status of VA and DOD Pharmaceutical Procurements 1 32 Appendix II Planned DOD and VA Joint Procurements 39 Appendix III VA’s CMOP Program 44 Appendix IV Comments From the Departm... |
| Date May 9, 2001 |
Report No. GAO-01-713T |
Title
United States General Accounting Office GAO Testimony
Before the Subcommittee on Health, Committee on Ways and Means, House of Representatives For Release on Delivery Expected at 2:00 p.m. Wednesday, May 9, 2001 MEDICARE Cost-Sharing Policies Problematic for Beneficiaries and Program
Statement of William J. Scanlon Director, Health Care Issues GAO-01-713T Madam Chairwoman and Members of the Subcom... |
| Date May 8, 2001 |
Report No. GAO-01-705T |
Title
United States General Accounting Office GAO Testimony
Before the Committee on Health, Education, Labor and Pensions, U.S. Senate For Release on Delivery Expected at 9:30 a.m. Tuesday, May 8, 2001 PEDIATRIC DRUG RESEARCH Substantial Increase in Studies of Drugs for Children, But Some Challenges Remain
Statement of Janet Heinrich Director, Health Care—Public Health Issues GAO-01-705T Chairman Jeff... |
| Date Jan. 29, 2001 |
Report No. GAO-01-183 |
Title
United States General Accounting Office GAO
January 2001 Report to the Ranking Member, Committee on Veterans’ Affairs, U.S. Senate VA DRUG FORMULARY Better Oversight Is Required, but Veterans Are Getting Needed Drugs GAO-01-183 Letter Appendixes
Appendix I: Scope and Methodology 3 24 29 33 34 Table 1: Percentage of Total Outpatient Prescriptions Filled for National Formulary Drugs by VISN and Me... |
| Date Jan. 19, 2001 |
Report No. GAO-01-286R |
Title
United States General Accounting Office Washington, DC 20548 January 19, 2001 The Honorable Tom Harkin The Honorable Olympia J. Snowe The Honorable Barbara A. Mikulski United States Senate The Honorable Henry A. Waxman House of Representatives Subject: Drug Safety: Most Drugs Withdrawn in Recent Years Had Greater Health Risks for Women The Food and Drug Administration (FDA) approves drugs for sale... |
| Date Nov. 27, 2000 |
Report No. GAO-01-176R |
Title
United States General Accounting Office Washington, DC 20548 November 27, 2000 The Honorable Michael M. Hash Acting Administrator Health Care Financing Administration Subject: Medicare+Choice: Oversight Lapses in HCFA’s Review of Humana’s 1998 Florida Contract Dear Mr. Hash: Last year, we reported that a large, experienced Medicare+Choice plan provided a prescription drug benefit with a covera... |
| Date Nov. 16, 2000 |
Report No. GAO-01-137 |
Title
United States General Accounting Office GAO
November 2000 Report to Congressional Requesters PRESCRIPTION DRUGS Drug Company Programs Help Some People Who Lack Coverage GAO-01-137 Contents Letter Appendix Tables
Appendix I: Scope and Methodology 3 16 Table 1: Reported Annual Income Limits for Eligibility in Patient Assistance Programs, 1998 Table 2: Programs Offering and Requiring Applications for... |
| Date Oct. 31, 2000 |
Report No. GAO-01-175R |
Title
United States General Accounting Office Washington, DC 20548 ERRATA Drug Prices Paid by DOD and VA Are, on Average, Lower Than Those Certified to HCFA as Best Price GAO-01-175R October 31, 2000 This correspondence has been modified to include technical clarifications. Robert H. Hast Managing Director Office of Special Investigations United States General Accounting Office Washington, DC 20548 Octo... |
| Date Oct. 19, 2000 |
Report No. GAO-01-69 |
Title
United States General Accounting Office GAO
October 2000 Report to Congressional Requesters INTERNET PHARMACIES Adding Disclosure Requirements Would Aid State and Federal Oversight GAO-01-69 Contents Letter Appendixes
Appendix I: Scope and Methodology 3 30 Appendix II: Actions by 28 States to Regulate Internet Pharmacies and Physicians Prescribing on the Basis of an Online Questionnaire Appendix I... |
| Date Oct. 4, 2000 |
Report No. GAO-01-34T |
Title
United States General Accounting Office GAO
For Release on Delivery Expected at 10:00 a.m., EDT Wednesday, October 4, 2000 Testimony
Before the Subcommittee on Criminal Justice, Drug Policy and Human Resources, Committee on Government Reform, U.S. House of Representatives ANTI-DRUG MEDIA CAMPAIGN Investigation of Actions Taken Concerning Alleged Excessive Contractor Cost
Statement of Robert H. Has... |
| Date Sept. 6, 2000 |
Report No. HEHS-00-162 |
Title
United States General Accounting Office GAO
September 2000 Report to Congressional Requesters STATE PHARMACY PROGRAMS Assistance Designed to Target Coverage and Stretch Budgets GAO/HEHS-00-162 Contents Letter Appendixes Tables
Appendix I: Scope and Methodology 3 26 Table 1: State Pharmacy Assistance Programs, Years Enacted and Operational 7 Table 2: Eligibility Requirements for State Pharmacy Assi... |
| Date Aug. 10, 2000 |
Report No. HEHS-00-140 |
Title
United States General Accounting Office GAO
August 2000 Report to Congressional Requesters PRESCRIPTION DRUGS Many Factors Affected FDA’s Approval of Selected “Pipeline” Drugs GAO/HEHS-00-140 Contents Letter Appendixes
Appendix I: Scope and Methodology 3 26 29 32 45 49 Appendix II: Approval Time Comparisons Appendix III: Approval Process for Claritin Appendix IV: Approval Process for Relafen... |
| Date Aug. 7, 2000 |
Report No. HEHS-00-118 |
Title
United States General Accounting Office GAO
August 2000 Report to Congressional Requesters PRESCRIPTION DRUGS Expanding Access to Federal Prices Could Cause Other Price Changes GAO/HEHS-00-118 Contents Letter Tables
Table 1: Pharmaceutical Pricing Terms Table 2: Prices for Select Prescription Drugs Commonly Used by the Elderly, February 2000 3 9 12 Abbreviations AMP AWP CBO DOD FCP FSS GSA HCFA HM... |
| Date May 25, 2000 |
Report No. T-HEHS-00-121 |
Title
United States General Accounting Office GAO
For Release on Delivery Expected at 10:00 a.m. Thursday, May 25, 2000 Testimony
Before the Subcommittee on Oversight and Investigations, Committee on Veterans’ Affairs, House of Representatives DOD AND VA HEALTH CARE Jointly Buying and Mailing Out Pharmaceuticals Could Save Millions of Dollars
Statement of Stephen P. Backhus, Director Veterans’ Affai... |
| Date May 11, 2000 |
Report No. T-HEHS-00-112 |
Title
United States General Accounting Office GAO
For Release on Delivery Expected at 9:30 a.m. Thursday, May 11, 2000 Testimony
Before the Subcommittee on Health, Committee on Ways and Means, House of Representatives PRESCRIPTION DRUGS Adapting Private Sector Management Methods for a Medicare Benefit
Statement of William J. Scanlon, Director Health Financing and Public Health Issues Health, Education, ... |
| Date March 22, 2000 |
Report No. T-HEHS-00-84 |
Title
United States General Accounting Office GAO
For Release on Delivery Expected at 10:00 a.m. Wednesday, March 22, 2000 Testimony
Before the Committee on Finance, U.S. Senate PRESCRIPTION DRUG BENEFITS Applying Private Sector Management Methods to Medicare
Statement of William J. Scanlon, Director Health Financing and Public Health Issues Health, Education, and Human Services Division GAO/T-HEHS-00-8... |
| Date March 1, 2000 |
Report No. HEHS-00-70R |
Title
- A
Accountability * Integrity * Reliability eGA0
United States General Accounting Washington, DC 20548 Office Health, Education, aud Human Services Division B-i.!84796 March 1,ZOOO The Honorable John D. Dingell Ranking Minority Member Committee on Commerce House of Representatives Subject: Mediaap: Premiums Dear Mr. Dingell: This letter is in response to your request for information on premiums f... |
| Date Feb. 16, 2000 |
Report No. T-HEHS/AIMD-00-100 |
Title
United States General Accounting Office GAO
For Release on Delivery Expected at 10:00 a.m. Wednesday, February 16, 2000 Testimony
Before the Subcommittee on Health and Environment, Committee on Commerce, House of Representatives PRESCRIPTION DRUGS Increasing Medicare Beneficiary Access and Related Implications
Statement of William J. Scanlon, Director Health Financing and Public Health Issues Heal... |
| Date Feb. 15, 2000 |
Report No. T-HEHS/AIMD-00-99 |
Title
United States General Accounting Office Testimony
Before the Subcommittee on Health, Committee on Ways and Means, House of Representatives Tuesday, February 15, 2000 PRESCRIPTION DRUGS Increasing Medicare Beneficiary Access and Related Implications
Statement of David M. Walker Comptroller General of the United States GA O
GAO/T-HEHS/AIMD-00-99 Mr. Chairman and Members of the Subcommittee: I am ple... |
| Date Feb. 9, 2000 |
Report No. T-HEHS-00-61 |
Title
United States General Accounting Office GAO
For Release on Delivery Expected at 10:30 a.m. Wednesday, February 9, 2000 Testimony
Before the Subcommittees on Health and Environment, and Oversight and Investigations, Committee on Commerce, and Subcommittee on Health, Committee on Veterans’ Affairs, House of Representatives ADVERSE EVENTS Surveillance Systems for Adverse Events and Medical Errors
S... |
| Date Feb. 1, 2000 |
Report No. T-HEHS-00-53 |
Title
United States General Accounting Office GAO
For Release on Delivery Expected at 10:00 a.m. Tuesday, Feb. 1, 2000 Testimony
Before the Committee on Health, Education, Labor, and Pensions, U.S. Senate ADVERSE DRUG EVENTS Substantial Problem but Magnitude Uncertain
Statement of Janet Heinrich, Associate Director Health Financing and Public Health Issues Health and Human Services Division GAO/T-HEHS-0... |
| Date Jan. 18, 2000 |
Report No. HEHS-00-21 |
Title
United States General Accounting Office GAO
January 2000 Report to Congressional Requesters ADVERSE DRUG EVENTS The Magnitude of Health Risk Is Uncertain Because of Limited Incidence Data GAO/HEHS-00-21 GAO United States General Accounting Office Washington, D.C. 20548 Health, Education, and Human Services Division B-281822 January 18, 2000 Congressional Requesters In 1998, about 2.7 billion presc... |
